Ground Truths • 13866 implied HN points • 02 Jan 26
- Low-dose aspirin for primary prevention in older adults generally causes more harm than benefit. It increases major bleeding and, in some trials, was linked to higher overall or cancer-related mortality without reducing cardiovascular events.
- Major guidelines now advise against routine aspirin for primary prevention in older adults, with age cutoffs varying by group. Aspirin still provides clear benefit for secondary prevention after events like heart attack, stroke, or stenting.
- There are hints aspirin might lower cancer incidence in specific subgroups (for example people with CHIP), but overall trial data in the elderly showed higher cancer deaths and CHIP testing isn’t part of routine care, so this is not an actionable reason to use aspirin now.